Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent

被引:17
作者
Fagete, Severine [1 ]
Ravn, Ulla [1 ]
Gueneau, Franck [1 ]
Magistrelli, Giovanni [1 ]
Kosco-Vilbois, Marie H. [1 ]
Fischer, Nicolas [1 ]
机构
[1] NovImmune SA, CH-1228 Plan Les Ouates, Switzerland
关键词
cross-reactive antibody; antibody arrays; chemotaxis; multiple targeting; affinity maturation; phage display; ANTIGEN INTERACTIONS; MOLECULAR EVOLUTION; CROSS-REACTIVITY; RECEPTOR CXCR3; INHIBITION; CELLS; CHEMOATTRACTANT; INFLAMMATION; RECRUITMENT; BLOCKADE;
D O I
10.4161/mabs.1.3.8527
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Chemokines are important mediators of the immune response that are responsible for the trafficking of immune cells between lymphoid organs and migration towards sites of inflammation. Using phage display selection and a functional screening approach, we have isolated a panel of single-chain fragment variable (scFv) capable of neutralizing the activity of the human chemokine CXCL10 (hCXCL10). One of the isolated scFv was weakly cross-reactive against another human chemokine CXCL9, but was unable to block its biological activity. We diversified the complementarity determining region 3 (CDR3) of the light chain variable domain (VL) of this scFv and combined phage display with high throughput antibody array screening to identify variants capable of neutralizing both chemokines. Using this approach it is therefore possible to engineer pan-specific antibodies that could prove very useful to antagonize redundant signaling pathways such as the chemokine signaling network.
引用
收藏
页码:288 / 296
页数:9
相关论文
共 28 条
[11]   Antibody multispecificity mediated by conformational diversity [J].
James, LC ;
Roversi, P ;
Tawfik, DS .
SCIENCE, 2003, 299 (5611) :1362-1367
[12]   Chemokine inhibition - why, when, where, which and how? [J].
Johnson, Z ;
Power, CA ;
Weiss, C ;
Rintelen, F ;
Ji, H ;
Ruckle, T ;
Camps, M ;
Wells, TNC ;
Schwarz, MK ;
Proudfoot, AEI ;
Rommel, C .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 :366-377
[13]  
Lefranc M-P., 2001, The Immunoglobulin FactsBook, P1
[14]   IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains [J].
Lefranc, MP ;
Pommié, C ;
Ruiz, M ;
Giudicelli, V ;
Foulquier, E ;
Truong, L ;
Thouvenin-Contet, V ;
Lefranc, G .
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 2003, 27 (01) :55-77
[15]   Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens [J].
Lloyd, C. ;
Lowe, D. ;
Edwards, B. ;
Welsh, F. ;
Dilks, T. ;
Hardman, C. ;
Vaughan, T. .
PROTEIN ENGINEERING DESIGN & SELECTION, 2009, 22 (03) :159-168
[16]   Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells [J].
Mach, F ;
Sauty, A ;
Iarossi, AS ;
Sukhova, GK ;
Neote, K ;
Libby, P ;
Luster, AD .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (08) :1041-1050
[17]   Chemokines derived from soluble fusion proteins expressed in Escherichia coli are biologically active [J].
Magistrelli, G ;
Gueneau, F ;
Muslmani, M ;
Ravn, U ;
Kosco-Vilbois, M ;
Fischer, N .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 334 (02) :370-375
[18]   Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis [J].
Mohan, Karkada ;
Issekutz, Thomas B. .
JOURNAL OF IMMUNOLOGY, 2007, 179 (12) :8463-8469
[19]   Antibody engineering for therapeutics [J].
Presta, L .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2003, 13 (04) :519-525
[20]   Manufacture of recombinant polyclonal antibodies [J].
Rasmussen, S. K. ;
Rasmussen, L. K. ;
Weilguny, D. ;
Tolstrup, A. B. .
BIOTECHNOLOGY LETTERS, 2007, 29 (06) :845-852